Celldex Therapeutics Stock Quote CLDX - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

26.22

Bid

25.01

Ask

28.17

Volume

0.00 Day's Range 0.00

22.9291 52 Week Range 53.18

Market Cap

1.74B

Previous Close

26.22

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

1,200,003

Shares Outstanding

66,344,236

Dividend Yield

PE Ratio

-12.33

Earnings Per Share (EPS)

-2.13

Revenue

6.88M

Net Profit

-141.43M

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung c... Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. Show more

Sector

In Vitro,in Vivo Diagnostics

Industry

In Vitro,in Vivo Diagnostics

Website

www.celldex.com

Headquarters

Wilmington, Delaware, USA

Founded

Celldex Therapeutics Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker CLDX. The last closing price for Celldex Therapeutics was $26.22. Over the last year, Celldex Therapeutics shares have traded in a share price range of $ 22.9291 to $ 53.18.

Celldex Therapeutics currently has 66,344,236 shares outstanding. The market capitalization of Celldex Therapeutics is $1.74 billion. Celldex Therapeutics has a price to earnings ratio (PE ratio) of -12.33.

Form 4 - Statement of changes in beneficial ownership of securities

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.77	-2.85290848462	26.99	28.19	26.195	647193	27.31598393	CS
4	0.17	0.652591170825	26.05	28.4	22.9291	1063045	26.389481	CS
12	-15.57	-37.2577171572	41.79	47	22.9291	1200003	31.14431592	CS
26	-6.67	-20.2797202797	32.89	47	22.9291	936949	33.65995127	CS
52	-5.93	-18.4447900467	32.15	53.18	22.9291	859159	36.98153361	CS
156	-9.68	-26.9637883008	35.9	53.18	19.85	679660	34.29790039	CS
260	23.68	932.283464567	2.54	57.2	1.5	746429	26.96243135	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AALAmerican Airlines Group Inc	$ 14.47 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 69.03 (0.00%)	0
AADIAadi Bioscience Inc	$ 2.48 (0.00%)	0
AACGATA Creativity Global	$ 0.9752 (0.00%)	0
AALAmerican Airlines Group Inc	$ 14.47 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 69.03 (0.00%)	0
AADIAadi Bioscience Inc	$ 2.48 (0.00%)	0
AACGATA Creativity Global	$ 0.9752 (0.00%)	0
AALAmerican Airlines Group Inc	$ 14.47 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	$ 69.03 (0.00%)	0
AADIAadi Bioscience Inc	$ 2.48 (0.00%)	0
AACGATA Creativity Global	$ 0.9752 (0.00%)	0